This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: May 13, 2002
Last updated: June 1, 2016
Last verified: June 2016

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.

PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.

Condition Intervention Phase
Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Biological: ziv-aflibercept Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: An Open-Label, Sequential Cohort Dose-Escalation Safety, Tolerability And Pharmacokinetic Study Of VEGF Trap In Patients With Incurable, Relapsed Or Refractory Solid Tumors Or Lymphoma

Resource links provided by NLM:

Further study details as provided by Regeneron Pharmaceuticals:

Study Start Date: November 2001
Primary Completion Date: March 2002 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the safety and tolerability of VEGF Trap in patients with incurable relapsed or refractory solid tumors or non-Hodgkin's lymphoma.
  • Determine the maximum tolerated dose of this drug in these patients.
  • Determine the pharmacokinetics of this drug in these patients.
  • Evaluate the ability of this drug to bind and inactivate circulating vascular endothelial growth factor (VEGF) in these patients.
  • Determine the dosing regimen that is optimal for neutralization of circulating VEGF in these patients.
  • Determine whether antibodies to this drug develop in these patients.
  • Assess, preliminarily, the ability of this drug to alter tumor vascular permeability and tumor growth in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive VEGF Trap subcutaneously once daily on days 1, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity.

Cohorts of 1-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 5 additional patients are treated at the MTD.

Patients are followed at 1 and 4 weeks.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.


Ages Eligible for Study:   25 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed incurable primary or metastatic solid tumor or non-Hodgkin's lymphoma

    • Relapsed after or is refractory (e.g., unresectable) to at least 2 standard chemotherapy regimens and rituximab
    • No standard curative surgery, chemotherapy, immunotherapy, other antitumor therapy, or radiotherapy options exist
  • No known or suspected squamous cell carcinoma of the lung
  • No prior or concurrent CNS (brain or leptomeningeal) metastases
  • No prior or concurrent primary intracranial tumor by MRI or CT scan



  • 25 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified


  • WBC at least 3,500/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL
  • No other severe or uncontrolled hematologic condition


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST and ALT no greater than 2 times ULN
  • Alkaline phosphatase no greater than 2 times ULN
  • PT, PTT, and INR normal


  • Creatinine no greater than ULN
  • No 1+ or greater proteinuria
  • No other severe or uncontrolled renal condition


  • Electrocardiogram normal
  • LVEF normal by echocardiogram or MUGA scan within the past 12 months or since completion of prior anthracycline
  • No severe or uncontrolled cardiovascular condition
  • No New York Heart Association class III or IV heart disease
  • No active coronary artery disease, angina, congestive heart failure, or arrhythmia
  • No myocardial infarction within the past 6 months
  • No prior or concurrent peripheral vascular disease, including:

    • Angiographically or ultrasonographically documented arterial or venous occlusive event
    • Symptomatic claudication
  • No untreated or uncontrolled hypertension
  • No treated blood pressure more than 160/100 mm Hg on at least 3 repeated determinations on separate days within the past 6 weeks
  • No symptomatic orthostatic hypotension


  • No severe or uncontrolled pulmonary condition
  • No pulmonary embolism


  • No prior hypersensitivity reactions to any recombinant proteins (e.g., VEGF Trap)
  • No severe or uncontrolled gastrointestinal, immunological, or musculoskeletal condition
  • No severe or uncontrolled psychiatric or adverse social circumstance that would preclude study
  • No active infection requiring antibiotics
  • HIV negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-barrier contraception during and for at least 3 months after study


Biologic therapy:

  • See Disease Characteristics
  • At least 3 weeks since prior immunotherapy
  • No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy

Endocrine therapy:

  • No concurrent adrenal corticosteroids, except low doses as replacement therapy in patients who have previously received suppressive doses or for adrenal insufficiency
  • No concurrent systemic hormonal contraceptive agents


  • See Disease Characteristics
  • At least 3 weeks since prior radiotherapy


  • See Disease Characteristics
  • At least 3 weeks since prior surgery (except fine needle biopsy/aspiration or removal/biopsy of a skin lesion)
  • No prior surgical procedure for correction or prophylaxis of peripheral vascular insufficiency or cerebral ischemic events


  • Recovered from prior therapy
  • At least 6 months since prior treatment for acute congestive heart failure
  • At least 30 days since prior investigational drugs
  • No concurrent standard or other investigational anticancer agents
  • No concurrent herbal supplements ("nutraceuticals")
  • No concurrent anticoagulant or antiplatelet drugs, (e.g., warfarin, heparin, aspirin, or other non-steroidal anti-inflammatory drugs) except selective cyclo-oxygenase-2 (COX-2) inhibitors for analgesia
  • No concurrent COX-2 inhibitors for tumor treatment or prophylaxis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00036946

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Study Chair: Jakob Dupont, MD Memorial Sloan Kettering Cancer Center
  More Information

Dupont J, Schwartz L, Koutcher J, et al.: Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. [Abstract] J Clin Oncol 22 (Suppl 14): A-3009, 197s, 2004.
Dupont J, Camastra D, Gordon MS, et al.: Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-776, 2003.

Responsible Party: Regeneron Pharmaceuticals Identifier: NCT00036946     History of Changes
Other Study ID Numbers: REGENERON-VGFT-ST-0103
CDR0000069343 ( Registry Identifier: PDQ (Physician Data Query) )
Study First Received: May 13, 2002
Last Updated: June 1, 2016

Keywords provided by Regeneron Pharmaceuticals:
unspecified adult solid tumor, protocol specific
stage IV grade 1 follicular lymphoma
stage IV grade 2 follicular lymphoma
stage IV grade 3 follicular lymphoma
stage IV adult diffuse small cleaved cell lymphoma
stage IV adult diffuse mixed cell lymphoma
stage IV adult diffuse large cell lymphoma
stage IV adult immunoblastic large cell lymphoma
stage IV adult lymphoblastic lymphoma
stage IV adult Burkitt lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent adult Burkitt lymphoma
stage IV mantle cell lymphoma
recurrent mantle cell lymphoma
recurrent marginal zone lymphoma
recurrent small lymphocytic lymphoma
stage IV small lymphocytic lymphoma
stage IV marginal zone lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
splenic marginal zone lymphoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on September 19, 2017